Tranexamic Acid in Reverse Total Shoulder Arthroplasty

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
Shoulder Joint DiseaseComplications; ArthroplastyIntraoperative ComplicationsBlood Loss, Surgical
Interventions
DRUG

Tranexamic Acid

Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.

DRUG

Placebo

Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.

Trial Locations (1)

48073

William Beaumont Hospital, Royal Oak

All Listed Sponsors
lead

William Beaumont Hospitals

OTHER

NCT02043132 - Tranexamic Acid in Reverse Total Shoulder Arthroplasty | Biotech Hunter | Biotech Hunter